India`s second biggest drug maker, Ranbaxy Laboratories (RLL) received approval to manufacture and market Coviro-LS kid and Coviro-LS kid DS, both double anti-retroviral (ARV) and fixed dose combination, dispersible tablets for children, in India. It has also filed the products with WHO Geneva for pre-qualification.
While Coviro-LS kid contains Lamivudine 20mg and Stavudjne 5mg, Coviro-LS kid DS contains the drugs in 40mg and 10mg strengths respectively. The products are bio-equivalent with the individual liquid formulations of the originators. The products are indicated for treatment of HIV infection in children.
``Ranbaxy is committed to develop innovative ARVs at affordable cost. We strongly believe that with these new formulations, we will be able to make accessible, a high quality and convenient treatment to a large number of IIIV-positive children who are therapeutically among the most neglected``, said Malvinder Mohan Singh, CEO and managing director, RLL.
Both the approved formulations are scored dispersible tablets, and are pleasantly flavoured. The products are designed to deliver two ARV drugs together in recommended strengths and simplify delivery of a more accurate treatment to children in resource poor settings. Last year the company had launched two triple ARV combinations for children.
The company presently has 15 ARVs of the WHO pre-qualification list of which three are USFDA approved.
Shares of the company gained Rs 4.95, or 1.26%, to settle at Rs 397.95. The total volume of shares traded was 253,322 at the BSE. (Thursday)